Document Type
Article
Publication Date
9-1-2019
Abstract
For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom and patient-reported outcomes management research is explained as it pertains to radiopharmaceutical clinical development. An effort already underway to support protocol authoring via an NCI Cancer Therapy Evaluation Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service aids incorporation of HRQOL, symptom and patient-reported outcomes management research into sponsored protocols.
Recommended Citation
Kunos, Charles A; Capala, Jacek; Dicker, Adam P; Movsas, Benjamin; Ivy, Susan Percy; and Minasian, Lori M, "Clinical Outcome Assessments Toolbox for Radiopharmaceuticals." (2019). Department of Radiation Oncology Faculty Papers. Paper 124.
https://jdc.jefferson.edu/radoncfp/124
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
31649885
Language
English
Comments
This article has been peer-reviewed. It is the author's final published version in Frontiers in Oncology, Volume 9, September 2019, Article Number 1028.
The published version is available at http://doi.org/10.3389/fonc.2019.01028. Copyright © Kunos et.al.